Gary W. Hoyle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gary W. Hoyle has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Chun-Ting Lee
Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Department of Medicine, SL-9, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112, USA
2 shared publicationsHalet G. Poovey
Department of Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
2 shared publicationsRoy J. Rando
Department of Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University Health Sciences Center, New Orleans, LA 70112, USA
2 shared publicationsArnold R. Brody
Program in Lung Biology, Section of Pulmonary Diseases, Environmental and Critical Care Medicine, Department of Medicine, Department of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana
1 shared publicationJian Li
Section of Pulmonary Diseases, Critical Care and Environmental Medicine, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana 70112, USA
1 shared publicationMitchell Friedman
Section of Pulmonary Diseases, Critical Care and Environmental Medicine, SL-9, Department of Medicine; and Tulane/Xavier Center for Bioenvironmental Research, Tulane University Health Sciences Center, 1430 Tulane Avenue, New Orleans, LA 70112;; Department of Environmental Health Sciences, School of Public Health and Tropical Medicine, Tulane University Health Sciences Center, New Orleans, La
1 shared publication
Latest Publications
- 1 October 2007
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 224 (1) , 19-28
Neuronal modulation of lung injury induced by polymeric hexamethylene diisocyanate in mice
- 1 October 2007
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 224 (1) , 19-28
Neuronal modulation of lung injury induced by polymeric hexamethylene diisocyanate in mice
- Open Access
- 1 February 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (2) , L430-L437
Tachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-κB via a Gq-dependent pathway
The respiratory tract is innervated by irritant-responsive sensory nerves, which, on stimulation, release tachykinin neuropeptides in the lung. Tachykinins modulate inflammatory responses to injury by binding to tachykinin (neurokinin) receptors present on various pulmonary cell types. In the present study, the activation of the proinflammatory transcription factor NF-κB in lung epithelial cells was investigated as a mechanism by which tachykinins stimulate inflammatory processes. In A549 human lung epithelial cells transfected with the tachykinin-1 receptor (Tacr1), treatment with the Tacr1 ligand substance P (SP) resulted in NF-κB activation, as judged by transcription of an NF-κB-luciferase reporter gene and production of interleukin-8, a chemokine whose expression is upregulated by NF-κB. SP caused a dose-dependent activation of NF-κB that was inhibited by the selective Tacr1 antagonist RP67580. Tacr1 is a G protein-coupled receptor capable of activating both the Gqand Gsfamilies of G proteins. Expression of inhibitory peptides and constitutively active G protein mutants revealed that Gqsignaling was both necessary for Tacr1-induced NF-κB activation and sufficient for NF-κB activation in the absence of any other treatment. Treatment with pharmacological inhibitors to investigate events downstream of Gqrevealed that Tacr1-induced NF-κB activation proceeded through an intracellular signaling pathway that was dependent on phospholipase C, calcium, Ras, Raf-1, MEK, Erk, and proteasome function. These results identify intracellular signaling mechanisms that underlie the proinflammatory effects of tachykinins, which previously have been implicated in lung injury and disease.
- 1 February 2007
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 292 (2) , L430-L437
Open AccessTachykinin-1 receptor stimulates proinflammatory gene expression in lung epithelial cells through activation of NF-κB via a Gq-dependent pathway
The respiratory tract is innervated by irritant-responsive sensory nerves, which, on stimulation, release tachykinin neuropeptides in the lung. Tachykinins modulate inflammatory responses to injury by binding to tachykinin (neurokinin) receptors present on various pulmonary cell types. In the present study, the activation of the proinflammatory transcription factor NF-κB in lung epithelial cells was investigated as a mechanism by which tachykinins stimulate inflammatory processes. In A549 human lung epithelial cells transfected with the tachykinin-1 receptor (Tacr1), treatment with the Tacr1 ligand substance P (SP) resulted in NF-κB activation, as judged by transcription of an NF-κB-luciferase reporter gene and production of interleukin-8, a chemokine whose expression is upregulated by NF-κB. SP caused a dose-dependent activation of NF-κB that was inhibited by the selective Tacr1 antagonist RP67580. Tacr1 is a G protein-coupled receptor capable of activating both the Gqand Gsfamilies of G proteins. Expression of inhibitory peptides and constitutively active G protein mutants revealed that Gqsignaling was both necessary for Tacr1-induced NF-κB activation and sufficient for NF-κB activation in the absence of any other treatment. Treatment with pharmacological inhibitors to investigate events downstream of Gqrevealed that Tacr1-induced NF-κB activation proceeded through an intracellular signaling pathway that was dependent on phospholipase C, calcium, Ras, Raf-1, MEK, Erk, and proteasome function. These results identify intracellular signaling mechanisms that underlie the proinflammatory effects of tachykinins, which previously have been implicated in lung injury and disease.
- 1 December 2003
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 14 (6) , 551-558
Neurotrophins and lung disease
- 1 December 2003
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 14 (6) , 551-558
Neurotrophins and lung disease
- 1 July 2003
- Published by American Industrial Hygiene Association (AIHA) in AIHA Journal
- Vol. 64 (4) , 439-444
An HDI Polyisocyanate Aerosol Exposure System for Large-Scale Animal Experiments
An exposure system that allows large-scale exposure of animals to 1,6-hexamethylene diisocyanate (HDI)-based polyisocyanates at a stable concentration and aerosol size distribution was developed. The HDI polyisocyanate aerosol is generated by nebulizing a solution of a commercial polyisocyanate product dissolved in acetone. The aerosol is delivered with a constant airflow into a horizontal flow chamber. Complete mixing of aerosol in the chamber is ensured by a circulating fan. This method has been used to generate atmospheres containing HDI polyisocyanates at a concentration of 10.46±0.23 mg/m3 over a 5-hour period. The overall mass median aerodynamic equivalent diameter was found to be 1.42 µm with a geometric standard deviation of 1.26. The HDI monomer concentration was 0.15±0.04 mg/m3. The average chamber acetone concentration was determined to be 2481±222 ppm (mean±standard deviation). Different HDI polyisocyanate concentrations in the chamber can be achieved by altering the concentration of the commercial polyisocyanate product in acetone and the chamber flow rate. The described exposure system will be useful for performing toxicological studies involving HDI polyisocyanates.
- 1 July 2003
- Published by American Industrial Hygiene Association (AIHA) in AIHA Journal
- Vol. 64 (4) , 439-444
An HDI Polyisocyanate Aerosol Exposure System for Large-Scale Animal Experiments
An exposure system that allows large-scale exposure of animals to 1,6-hexamethylene diisocyanate (HDI)-based polyisocyanates at a stable concentration and aerosol size distribution was developed. The HDI polyisocyanate aerosol is generated by nebulizing a solution of a commercial polyisocyanate product dissolved in acetone. The aerosol is delivered with a constant airflow into a horizontal flow chamber. Complete mixing of aerosol in the chamber is ensured by a circulating fan. This method has been used to generate atmospheres containing HDI polyisocyanates at a concentration of 10.46±0.23 mg/m3 over a 5-hour period. The overall mass median aerodynamic equivalent diameter was found to be 1.42 µm with a geometric standard deviation of 1.26. The HDI monomer concentration was 0.15±0.04 mg/m3. The average chamber acetone concentration was determined to be 2481±222 ppm (mean±standard deviation). Different HDI polyisocyanate concentrations in the chamber can be achieved by altering the concentration of the commercial polyisocyanate product in acetone and the chamber flow rate. The described exposure system will be useful for performing toxicological studies involving HDI polyisocyanates.
- 1 November 2001
- Published by Elsevier in Developmental Biology
- Vol. 239 (2) , 338-349
Overexpression of PDGF-A in the Lung Epithelium of Transgenic Mice Produces a Lethal Phenotype Associated with Hyperplasia of Mesenchymal Cells
- 1 November 2001
- Published by Elsevier in Developmental Biology
- Vol. 239 (2) , 338-349
Overexpression of PDGF-A in the Lung Epithelium of Transgenic Mice Produces a Lethal Phenotype Associated with Hyperplasia of Mesenchymal Cells
- 1 April 2001
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 24 (4) , 365-367
IL-9 and Lung Fibrosis: A Th2 Good Guy?
- 1 April 2001
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 24 (4) , 365-367
IL-9 and Lung Fibrosis: A Th2 Good Guy?